THE PARTICIPATION OF IMMUNE AND INFLAMMATORY MECHANISMSIN THE PATHOGENESIS OF CORONARY ATHEROSCLEROSIS

Abstract

It was revealed that in development of a coronary atherosclerosis, participate the immune-mediated mechanisms. In blood of patients with coronary atherosclerosis the maintenance of the basic classes cytokines (IL-1 β, IL-2, IL-6, IL-8, TNF-a) were increased. Development of acute coronary insufficiency is accompanied by additional increase of levels of the data cytokines. The accessory of the cytokine activity to a coronary atherosclerosis was confirmed at studying the maintenance mRNA cytokines in a vascular wall. Thus in a zone atheromatous (aorta) it was synthesized mainly mRNA IL-2, while in a zone lipomatosis (a beam radial artery) it is formed nonspecific immune reaction with development of the mRNA IL-1 and IL-6. For patients with rheumatoid arthritis typically more active defeat of a coronary arteries, in comparison with healthy persons. Chronic immune-mediated process in frameworks of the autoimmune pathology can serve a trigger for accelerated development ischemic heart disease. The General immune-inflammatory mechanisms which participate in pathogenesis of the ischemic heart disease and rheumatoid arthritis, allow to spend the certain parallels between atherosclerotic process and autoimmune pathology.

Keywords

coronary atherosclerosis / rheumatoid arthritis / cytokines (IL-1 β / IL-2 / IL-6 / IL-8 / TNF-a / TGFb1) / IL-2 / IL-6 / IL-8 / TNF-a / TGFb1)

References

[1] Карпов Р.С., Дудко В.А. Атеросклероз. - Томск: STT, 1998. - 656 с.

[2] Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis // Nature. 2011;473:317-325.

[3] Demuth K., Myara I., Moatti N. Biology of the endothelial cell and atherogenesis. [Review] // Annales de Biologie Clinique. - 1995. - 53(4). - P. 171-91.

[4] Wensley F., Gao P., Burgess S., et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data // BMJ. 2011;342:d548.

[5] Ait-Oufella H., Taleb S., Mallat Z., Tedgui A. Recent advances on the role of cytokines in atherosclerosis // Arterioscler Thromb Vasc Biol. 2011;31:969-979.

[6] Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis // Cell. 2011;145:341-355

[7] Watanabe T., Shimokama T., Haraoka S., Kishikawa H. T lymphocytes in atherosclerotic lesions // Annals of the New York Academy of Sciences. - 1995. - Vol. 748. - Р. 40-55.

[8] Frostegard J., Ulfgren A.K, Nyberg P. et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines // Atherosclerosis. - 1999. - Vol. 145. - Р. 33-43.

[9] Bekkering S., Quintin J., Joosten L. A.B., van der Meer Jos W.M., et al. Oxidized Low-Density Lipoprotein Induces Long-Term Proinflammatory Cytokine Production and Foam Cell Formation via Epigenetic Reprogramming of Monocytes // Significance Arterioscler Thromb Vasc Biol. 2014;34:8 1731-1738, published online before print June 5 2014, doi:10.1161/ATVBAHA.114.303887

[10] Shoenfeld Y., Sherer Y., George J., Harats D. Autoantibodies associated with atherosclerosis // Ann. Med. - 2000. - Vol. 32, Suppl., № 1. - Р. 37-40.

[11] Craig W.Y. Autoantibodies against oxidized low density lipoprotein: a review of clinical findings and assay methodology. [Review]. Journal of Clinical Laboratory Analysis. - 1995. - 9(1). - Р. 70-4.

[12] Stemme S., Faber B., Holm J. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein // Proceedings of the National Academy of Sciences of the United States of America. - 1995. - Vol. 92, № 9. - Р. 3893-7.

[13] Климов А.Н. Аутоиммунная теория патогенеза и концепция модифицированных липопротеидов // Вест. АМН СССР. - 1990. - № 11. - С. 30-36.

[14] Нагорнев В.А. Атерогенез и иммунное воспаление // Архив патологии. - 1995. - № 3. - С. 6-14.

[15] Hansson G.K. Immune mechanisms in atherosclerosis // Arterioscler. Thromb. Vasc. Biol. - 2001. - Vol. 21. - P. 1876-1890.

[16] Ross R. Atherosclerosis is an inflammatory disease // N. Engl. J. Med. - 1999. - Vol. 340. - P. 115-121.

[17] Hansson G.K., Hermansson A. The immune system in atherosclerosis // Nat Immunol. 2011;12:204-212.

[18] Introna M., Mantovani A. Early activation signals in endothelial cells: stimulation by cytokines // Arterioscler. Thromh. Vase. Biol. - 1997. - Vol. 17. - P. 423-428.

[19] van der Wal A.C., Becker A.E. Immune and inflammatory responses in human atherosclerotic plaque // Schultheiss H., Schwimrnbeck P. eds. The role of immune mechanisms in cardiovascular disease. Berlin. - 1997. - Р. 205-213.

[20] Bekkering S., Joosten L.A., Meer J.W., Netea M.G., et al. Trained innate immunity and atherosclerosis // Curr Opin Lipidol. 2013;24:487-92

[21] Lijnen P.J., Petrov V.V., Fagard R.H. Induction of cardiac fibrosis by transforming growth factor-beta (1) // Mol. Genet. Metab. - 2000. - Vol. 71(1-2). - P. 418-35.

[22] Zernecke A. Weber C. Chemokines in Atherosclerosis: Proceedings Resumed // Arterioscler Thromb Vasc Biol. 2014;34:4 742-750, published online before print January 16 2014, doi:10.1161/ATVBAHA.113.301655

[23] Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways // Physiol Rev. 2006;86:515-581.

[24] Tashiro H., Shimokawa H., Yamamoto K., Momohara M. Altered plasma levels of cytokines in patients with ischemic heart disease // Coron. Artery Dis. - 1997. - Vol. 8, № 3-4. - Р. 143-7.

[25] Тепляков А.И., Кручинский Н.Г., Прищепова Е.В. и др. Роль молекул клеточной адгезии и цитокинов в регуляции межклеточных взаимодействий при атеросклерозе // Ангиология и сосудистая хирургия. - 1999. - Т. 5., № 3. - С. 11-15.

[26] Parissis J., Venetsanou K., Ziras N. Abnormal cytokine expression during the cours of acute myocardial ifarction // Eur. Heart J. - 1998. - Vol.19, Abstr., Suppl. - P.508.

[27] Swirski FK. Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure // Science. 2013;339:161-166.

[28] de Jager S.C., Bot I., Kraaijeveld A.O., Korporaal S.J., et al. Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation // Arterioscler Thromb Vasc Biol. 2013;33:e75-e83

[29] Kishikawa H., Shimokama T., Watanabe T. Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima: role of cell-mediated immunity in human atherogenesis // Virchows Arch. A. Pathol. Anat. Histopathol. - 1993. - Vol. 423. - P.433-442.

[30] McManus DD, Beaulieu LM, Mick E, Tanriverdi K, et al. Relationship among circulating inflammatory proteins, platelet gene expression, and cardiovascular risk // Arterioscler Thromb Vasc Biol. 2013;33:2666-2673.

[31] Nabata T., Fukuo K., Kitano S. et al. IL-2 modulates the responsiveness to angiotensin II in cultured vascular smooth muscle cells // Atherosclerosis. 1997. Vol. 133(1). Р.23-30.

[32] Szekanecz Z., Shah M.R., Pearce W.H. Human atherosclerotic abdomil aortic aneurisms produce IL-6 and IFN-gamma but not IL-2 and IL-4: possible role for IL-6 and IFN-gamma in vascular inflammation // Agents Actions. - 1994. - Vol. 42(3-4). - P. 159-162.

[33] Danesh J., Collins R., Appleby P., Peto R et al. Fibrinogen, C-reactive protein, albumin or white cell count: meta-analyses of prospective studies of coronary heart disease // JAMA. - 1998. - Vol. 279. - Р. 1477-1482.

[34] Ridker PM, Howard CP, Walter V, Everett B, Group CPI. Effects of interleukin-1beta inhibition with canakinumab on hemaglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial // Circulation. 2012; 126:2739-2748.

[35] Niu W., Liu Y., Qi Y., Wu Z., et al. Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing Mendelian randomization approach // Int J Cardiol. 2012;157:243-252.

RIGHTS & PERMISSIONS

Mazurov V.I., Stolov S.V., Belyaeva I.B., Trofimov E.A.